Some aspects provide novel dofetilide derivatives and pharmaceutical compositions containing the same that are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.

The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.

The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.

Electrode or electrolyte additives for energy storage devices comprising symmetrical or asymmetrical alkylsulfonyl imide or cyclic alkylene sulfonylimide salts are disclosed. The energy storage device comprises a first electrode and a second electrode, wherein at least one of the first electrode and the second electrode is a Si-based electrode, a separator between the first electrode and the second electrode, and an electrolyte composition. Symmetrical or asymmetrical alkylsulfonyl imide or cyclic alkylene sulfonylimide salts may serve as additives to the electrodes or to the electrolyte composition, or both.

Electrode or electrolyte additives for energy storage devices comprising symmetrical or asymmetrical alkylsulfonyl imide or cyclic alkylene sulfonylimide salts are disclosed. The energy storage device comprises a first electrode and a second electrode, wherein at least one of the first electrode and the second electrode is a Si-based electrode, a separator between the first electrode and the second electrode, and an electrolyte composition. Symmetrical or asymmetrical alkylsulfonyl imide or cyclic alkylene sulfonylimide salts may serve as additives to the electrodes or to the electrolyte composition, or both.

An electrolyte including an additive of compound of formula I, ##STR00001## wherein n is an integer ranging from 0 to 10; R.sub.1 and R.sub.2 are each independently selected from a substituted or unsubstituted C.sub.1-C.sub.10 alkylidene group, a substituted or unsubstituted C.sub.2-C.sub.10 alkenylene group, or a substituted or unsubstituted C.sub.1-C.sub.10 alkyleneoxy group; A.sub.1 selected from CH, C, N, S, O, B or Si; A.sub.2 is selected from CH—R.sub.3, N—R.sub.3, S, O, B—R.sub.3 or SiH—R.sub.3; A.sub.3 selected from CH.sub.2, CH, C, N, S, O, B or Si; R.sub.3 is selected from hydrogen, halogen, a substituted or unsubstituted C.sub.1-C.sub.10 alkyl group, or a substituted or unsubstituted C.sub.3-C.sub.10 cycloalkyl group; X.sub.1 is selected from a substituted or unsubstituted C.sub.1-C.sub.10 alkylidene group, a substituted or unsubstituted C.sub.2-C.sub.10 alkenylene group, ═R.sup.c═, or ═R.sup.c—, wherein R.sup.c is selected from a substituted or unsubstituted C.sub.2-C.sub.6 alkylidene group.

An electrolyte including an additive of compound of formula I, ##STR00001## wherein n is an integer ranging from 0 to 10; R.sub.1 and R.sub.2 are each independently selected from a substituted or unsubstituted C.sub.1-C.sub.10 alkylidene group, a substituted or unsubstituted C.sub.2-C.sub.10 alkenylene group, or a substituted or unsubstituted C.sub.1-C.sub.10 alkyleneoxy group; A.sub.1 selected from CH, C, N, S, O, B or Si; A.sub.2 is selected from CH—R.sub.3, N—R.sub.3, S, O, B—R.sub.3 or SiH—R.sub.3; A.sub.3 selected from CH.sub.2, CH, C, N, S, O, B or Si; R.sub.3 is selected from hydrogen, halogen, a substituted or unsubstituted C.sub.1-C.sub.10 alkyl group, or a substituted or unsubstituted C.sub.3-C.sub.10 cycloalkyl group; X.sub.1 is selected from a substituted or unsubstituted C.sub.1-C.sub.10 alkylidene group, a substituted or unsubstituted C.sub.2-C.sub.10 alkenylene group, ═R.sup.c═, or ═R.sup.c—, wherein R.sup.c is selected from a substituted or unsubstituted C.sub.2-C.sub.6 alkylidene group.

The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

The present invention provides compounds of formula (I), ##STR00001##
wherein: R.sub.1 is unsubstituted C.sub.1-C.sub.6 alkyl; L.sub.a is substituted or unsubstituted C.sub.1-C.sub.6 alkyl linker, substituted or unsubstituted C.sub.3-C.sub.10 carbocycle, substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, or substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S; and R.sub.2 and R.sub.3 are each, independently, H, substituted or unsubstituted C.sub.1-C.sub.6 alkyl, or substituted or unsubstituted C.sub.6-C.sub.10 aryl; or alternatively, R.sub.2 and R.sub.3, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S or a substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S. The invention also provides pharmaceutical compositions and methods for treating neurological diseases, such as multiple sclerosis.